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A
 
BSTRACT
 
Background
 
Most patients with familial primary
pulmonary hypertension have defects in the gene for
bone morphogenetic protein receptor II (
 
BMPR2
 
), a
member of the transforming growth factor 
 
b
 
 (TGF-
 
b
 
)
superfamily of receptors. Because patients with he-
reditary hemorrhagic telangiectasia may have lung
disease that is indistinguishable from primary pulmo-
nary hypertension, we investigated the genetic basis
of lung disease in these patients.
 
Methods
 
We evaluated members of five kindreds
plus one individual patient with hereditary hemor-
rhagic telangiectasia and identified 10 cases of pul-
monary hypertension. In the two largest families, we
used microsatellite markers to test for linkage to genes
encoding TGF-
 
b
 
–receptor proteins, including endoglin
and activin-receptor–like kinase 1 (
 
ALK1
 
), and 
 
BMPR2.
 
In subjects with hereditary hemorrhagic telangiecta-
sia and pulmonary hypertension, we also scanned
 
ALK1
 
 and 
 
BMPR2
 
 for mutations.
 
Results
 
We identified suggestive linkage of pulmo-
nary hypertension with hereditary hemorrhagic telan-
giectasia on chromosome 12q13, a region that includes
 
ALK1.
 
 We identified amino acid changes in activin-
receptor–like kinase 1 that were inherited in subjects
who had a disorder with clinical and histologic fea-
tures indistinguishable from those of primary pulmo-
nary hypertension. Immunohistochemical analysis in
four subjects and one control showed pulmonary vas-
cular endothelial expression of activin-receptor–like
kinase 1 in normal and diseased pulmonary arteries.
 
Conclusions
 
Pulmonary hypertension in associa-
tion with hereditary hemorrhagic telangiectasia can
involve mutations in 
 
ALK1.
 
 These mutations are as-
sociated with diverse effects, including the vascular
dilatation characteristic of hereditary hemorrhagic tel-
angiectasia and the occlusion of small pulmonary ar-
teries that is typical of primary pulmonary hyperten-
sion. (N Engl J Med 2001;345:325-34.)
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ULMONARY hypertension, defined as the
sustained elevation of mean pulmonary arte-
rial pressure above 25 mm Hg at rest and 30
mm Hg during exercise, is a major cause of
progressive right-sided heart failure leading to pre-
mature death.
 
1
 
 Pulmonary hypertension often results
from chronic lung disease leading to hypoxemia, recur-
rent thromboembolism, or left-sided heart disease, but
the pathogenesis is poorly understood. Less common-
P
 
ly, a primary defect of the pulmonary arterial vascu-
lature — characterized by increased medial thickness,
intimal fibrosis, and plexiform lesions of capillary-like
channels — causes occlusion of small pulmonary ar-
teries, a condition known as primary pulmonary hy-
pertension.
 
2,3
 
Primary pulmonary hypertension has an incidence
of 1 to 2 cases per million people per year.
 
4
 
 The disease
may occur at any age but has a peak onset in the third
decade of life. Untreated patients with this progressive
condition have a median survival of less than three
years after diagnosis.
 
5
 
 At least 6 percent of patients
with primary pulmonary hypertension have a family
history of the condition.
 
4
 
 Kindreds demonstrate au-
tosomal dominant inheritance with markedly reduced
penetrance of the gene associated with primary pul-
monary hypertension; a proportion of those who in-
herit the gene have no symptoms.
 
6
 
 The gene for pri-
mary pulmonary hypertension, which encodes bone
morphogenetic protein receptor II (
 
BMPR2
 
) and is
located on human chromosome 2,
 
7-9
 
 is a member of
the transforming growth factor 
 
b
 
 (TGF-
 
b
 
) superfam-
ily of receptors (Fig. 1).
 
10-12
 
Pulmonary hypertension that is clinically and his-
tologically indistinguishable from primary pulmonary
hypertension may occur in persons with hereditary
hemorrhagic telangiectasia, an autosomal dominant
vascular dysplasia.
 
13,14
 
 Abnormalities in endothelial cells
in patients with hereditary hemorrhagic telangiectasia
are associated with mucocutaneous telangiectases.
The New England Journal of Medicine 
Downloaded from nejm.org on September 29, 2012. For personal use only. No other uses without permission. 
 Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
 326
 
·
 
N Engl J Med, Vol. 345, No. 5
 
·
 
August 2, 2001
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
 
These lead to recurrent epistaxis and gastrointestinal
blood loss as well as arteriovenous malformations, par-
ticularly in the pulmonary, hepatic, and cerebral circu-
lations.
 
15
 
 Pulmonary arteriovenous malformations cre-
ate clinically significant right-to-left shunts, causing
hypoxemia, paradoxical embolism, stroke, and cerebral
abscesses.
 
16
 
 Mutations in two genes encoding addi-
tional TGF-
 
b
 
 receptors — namely, endoglin and ac-
tivin-receptor–like kinase 1 (
 
ALK1
 
) — which are lo-
cated on chromosomes 9 and 12, respectively, underlie
hereditary hemorrhagic telangiectasia (Fig. 1).
 
12,17,18
 
We investigated the genetic basis of pulmonary hy-
pertension in subjects with hereditary hemorrhagic
telangiectasia. We identified kindreds affected by he-
reditary hemorrhagic telangiectasia and pulmonary hy-
pertension, determined the clinical and pathological
features of the cohort, and then searched for molecu-
lar genetic defects within the TGF-
 
b
 
–receptor path-
way. The analysis was undertaken by the University of
Leicester, Leicester, United Kingdom, which holds
the data.
 
METHODS
 
Clinical Evaluation
 
Written informed consent was obtained from all participants in
accordance with the requirements of the ethics committees of the
Leicestershire Health Authority, United Kingdom, and the Ministry
of Health, Auckland, New Zealand, and the institutional review
board of the Vanderbilt University Medical Center. Between April
and September 2000, all family members underwent pedigree analy-
sis and clinical assessment. Hereditary hemorrhagic telangiectasia
was diagnosed with the use of current international consensus cri-
teria. These require the presence of any three of the following: an
affected first-degree relative, recurrent spontaneous epistaxis, mu-
cocutaneous telangiectasia, and documented visceral manifesta-
tions.
 
19
 
 The diagnosis of pulmonary hypertension was determined
through clinical evaluation, chest radiography, electrocardiography,
Doppler echocardiography, right-heart catheterization, and histo-
logic examination of tissue obtained by excision of a lung or at au-
topsy. Other known causes of elevated pulmonary arterial pressure
(for example, chronic lung disease associated with hypoxemia,
thromboembolism, intracardiac shunting, and left ventricular fail-
ure) were excluded. The diagnosis was established without knowl-
edge of genotypic status. To determine the prevalence of mutations
in 
 
ALK1
 
 in subjects with primary pulmonary hypertension who
had no personal or family history of hereditary hemorrhagic telan-
giectasia, we also assessed 11 subjects with familial primary pulmo-
nary hypertension and 24 subjects with sporadic primary pulmonary
hypertension, in whom the results of analysis for mutations in
 
BMPR2
 
 were negative; the clinical features of these subjects have
previously been described.
 
20,21
 
Genetic Studies
 
Linkage Analysis
 
DNA was isolated from peripheral-blood lymphocytes, paraffin-
embedded lung tissue, or dried blood spots from family members
as indicated in Figures 2 and 3.
 
22,23
 
 Genetic-linkage analysis was
performed in the largest families, Family 1 and Family 2, with the
use of the following polymorphic microsatellite markers: D9S60,
D9S315, and D9S61 for endoglin; D12S347, D12S368, and
D12S325 for 
 
ALK1;
 
 and D2S2289, D2S346, and D2S3009 for
 
BMPR2,
 
 as previously described.
 
24
 
 Two-point lod scores were cal-
culated with the use of the MLINK program.
 
25
 
Identification of Mutations in 
 
ALK1
 
 and 
 
BMPR2
 
The protein-coding sequence of 
 
ALK1
 
 (exons 2 through 10) was
amplified from genomic DNA with the use of primers complemen-
tary to the intronic sequences near the intron–exon boundaries, as
previously described.
 
26
 
The fragments were amplified by the polymerase chain reaction
(PCR) and excess primer was removed from the amplified fragments
with the use of a purification kit (QIAquick, Qiagen, Crawley, West
Sussex, United Kingdom) and sequenced with a dye-terminator cy-
cle-sequencing system (ABI PRISM 377, Perkin–Elmer Applied
Biosystems, Foster City, Calif.). Analysis of 
 
BMPR2
 
 sequence (ex-
ons 1 through 13) and gene dosage (exons 1 and 12) was performed
in each family member with pulmonary hypertension as previously
described
 
10,21
 
 (information on primer sequences is available as Sup-
plementary Appendix 1 with the full text of this article at http://
www.nejm.org).
 
Confirmation of Mutations and Segregation of Genotypes
 
Identified variants of 
 
ALK1
 
 were confirmed by resequencing of
independent samples or, for the substitution of thymine for cytosine
at position 1450 (Family 1) and the deletion of cytosine at position
37 (Family 5), by restriction-enzyme digestion with 
 
Fnu
 
4HI. For
the latter, the required exons were amplified, digested with restric-
tion enzyme, and size-fractionated on a 3 percent agarose gel. The
presence or absence of sequence variants in DNA samples from fam-
ily members and from 75 normal controls was also ascertained by
sequence analysis or restriction-enzyme digestion.
 
Histologic and Immunohistochemical Analysis
 
Normal lung tissue was obtained from unused material excised
from donors for heart–lung transplantation and diseased lung from
four subjects in Families 1 and 3 (Table 1). For immunohistochem-
ical analysis, sections were incubated at a dilution of 1:80 with either
a polyclonal antibody against activin-receptor–like kinase 1 (provid-
ed by Dr. D. Marchuk) or the monoclonal anti–endothelial-cell
marker anti-CD31 (JC/70A, from Dako, Ely, Cambridgeshire,
United Kingdom) for 60 minutes at room temperature and washed
before incubation with biotinylated secondary antibody. Antigen
was visualized with the use of the avidin–biotin–peroxidase tech-
nique (Vectastain ABC, Vector Laboratories, Peterborough, United
Kingdom) with diaminobenzidine substrate. The specificity of im-
munostaining was demonstrated by the absence of signal in sections
incubated with control mouse IgG (Sigma, St. Louis) or in sections
processed after omission of the primary antibody.
 
RESULTS
 
We identified five kindreds (Families 1, 2, 3, 4, and
6) and one individual patient (in Family 5) (Fig. 2 and
3) affected by hereditary hemorrhagic telangiectasia,
among whom there were 10 cases of pulmonary hy-
pertension (Table 1). Stigmata of hereditary hemor-
rhagic telangiectasia were not observed in five of these
subjects, each of whom was less than 30 years of age
(Table 1). Family 1 was noteworthy for the early age
of onset of pulmonary hypertension in three members
(Table 1 and Fig. 2). Pulmonary arteriovenous mal-
formations were detected in Subject II-1 from Family
3 and Subject II-1 from Family 5; in the latter sub-
ject, the malformation was embolized after the onset
of pulmonary hypertension. In the remaining eight
subjects with pulmonary hypertension, pulmonary ar-
teriovenous malformations were ruled out through a
combination of chest radiography, high-resolution hel-
ical computed tomography of the thorax, studies of
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Figure 1.
 
 Signaling Pathway of the Transforming Growth Factor 
 
b
 
 (TGF-
 
b
 
) Superfamily.
In the extracellular space, ligands to the TGF-
 
b
 
 superfamily of receptors bind either to an accessory
protein, which presents the ligand to the type II receptor, or directly to the type II receptor on the cell
membrane. The binding of the ligands to the type II receptor then leads to binding of the type I receptor
to form a heteromeric receptor complex at the cell surface. This results in phosphorylation and acti-
vation of the kinase domain of the type I receptor, which initiates phosphorylation of cytoplasmic sig-
naling proteins termed receptor Smads (R-Smads). Phosphorylated R-Smad binds to a collaborating
Smad (Co-Smad), and the resulting complex moves from the cytoplasm into the nucleus. The Smad
complex associates with a DNA-binding partner in the cell nucleus and interacts with various other
transcription factors in a cell-specific manner to regulate gene transcription and to mediate the effects
of signaling by the TGF-
 
b
 
 superfamily of receptors at the cellular level. Germ-line mutations of the
gene encoding the type II receptor, bone morphogenetic protein receptor II, underlie primary pulmo-
nary hypertension. Defects of the type I receptor, activin-receptor–like kinase 1, and the accessory pro-
tein, endoglin, cause hereditary hemorrhagic telangiectasia. In addition, mutations in the 
 
ALK1
 
 gene
also predispose subjects to the development of pulmonary hypertension. The specific extracellular lig-
ands, cell-surface receptors, cytoplasmic Smad proteins, and nuclear transcription factors that are in-
volved with signaling of bone morphogenetic protein II and activin-receptor–like kinase I in the pul-
monary circulation have not been identified.
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arterial oxygen saturation, and pulmonary angiography
and hemodynamic studies or were excluded on exam-
ination of excised lung tissue or at autopsy.
Analysis of three polymorphic markers on chromo-
some 12 supported linkage of the disease to the 
 
ALK1
 
locus in two families (likelihood of independent coin-
heritance, 1 in 100 and 1 in 125 in Families 1 and 2,
respectively). Because mutations in 
 
ALK1
 
 are known
to cause hereditary hemorrhagic telangiectasia, the
nine exons encoding the protein product were ampli-
fied and sequenced in probands with pulmonary hy-
pertension from five families (Families 1, 2, 3, 4, and
6) and one subject from Family 5. Novel heterozygous
sequence variants of 
 
ALK1
 
 were identified in the ge-
nomes of probands in four of five kindreds (Families
1, 2, 3, and 4) and one subject from Family 5 who
had been adopted and had no available family history
(Table 1 and Fig. 4). A deletion of a single nucleotide
(cytosine) at position 37 in exon 2 in Subject II-1 from
Family 5 and a substitution (thymine for cytosine) at
position 1468 in exon 10 in Family 4 are predicted
to lead to premature truncation of the mature protein,
by changing the reading frame and by introducing a
stop codon, respectively. 
Three sequence variants lead to alterations in 1 of
the 503 amino acids of the activin-receptor–like ki-
nase 1: a deletion of an aspartic acid at position 254
encoded by exon 6 (Family 3), a substitution of tryp-
tophan for arginine at position 411 encoded by exon
8 (Family 2), and a substitution of tryptophan for
arginine at position 484 encoded by exon 10 (Fam-
ily 1) (Table 1). No mutations in 
 
ALK1
 
 were detected
in 11 subjects with familial cases and 24 subjects with
sporadic cases of isolated primary pulmonary hyper-
tension, who were known to be negative for mutations
in 
 
BMPR2.
 
In Family 6, a previously reported 
 
ALK1
 
 sequence
variant was detected in Subject III-2, who had hered-
itary hemorrhagic telangiectasia (Fig. 3).
 
26
 
 However,
segregation analysis demonstrated that this 
 
ALK1
 
 vari-
ant was not inherited by Subjects IV-3, V-1, and V-2
(Fig. 3). To investigate the genetic basis of the pul-
monary hypertension in Subject V-1 further, we per-
formed mutational analysis of 
 
BMPR2.
 
 A partial dele-
tion in 
 
BMPR2
 
 that included exon 12 was identified
and shown to be maternally inherited (Table 1). Sub-
ject IV-4, who was from an unrelated family, reported
no personal or family history of pulmonary hyperten-
sion, in keeping with the low penetrance of mutant
 
BMPR2 
 
alleles.
 
10,20,29
 
 Thus, the presence of both
 
ALK1
 
-associated hereditary hemorrhagic telangiecta-
sia and 
 
BMPR2-related pulmonary hypertension in
Family 6 may be due to chance alone. No mutations
in BMPR2 were identified in probands with pulmo-
nary hypertension from Families 1, 2, 3, and 4 or in
Subject II-1 from Family 5.
To support the likelihood that these novel variants
of ALK1 cause disease, we first confirmed that each
Figure 2. Segregation of the Cytosine-to-Thymine Mutation at Position 1450 in ALK1 with Pulmonary Hypertension and Hereditary
Hemorrhagic Telangiectasia in Family 1.
The DNA-sequence chromatograms for the subjects tested are shown below the pedigree. Unaffected family members (Subjects
II-3, I-2, and II-5) have two normal alleles (cytosine in blue) at position 1450 of ALK1. Family members with pulmonary hypertension,
hereditary hemorrhagic telangiectasia, or both (Subjects II-2, III-1, III-2, III-3, and II-4) have one normal allele (cytosine in blue) and
one mutant allele (thymine in red) at position 1450, indicated by the letter Y. Squares denote male family members, circles female
family members, symbols with a slash deceased family members, black symbols members with both pulmonary hypertension and
hereditary hemorrhagic telangiectasia, gray symbols members with hereditary hemorrhagic telangiectasia only, hatched symbols
members with pulmonary hypertension only, and open symbols members unaffected by either condition.
II-2
I
1 2
2 31
3
II
III
YG G YG G C GG CG G Y GG Y GG G Y G G C G
III-1 II-3 I-2 III-2 III-3 II-4 II-5
4 5 6 7
42 31 5 6
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variant cosegregated with the disease in available af-
fected family members, as shown for Family 1 (Fig. 2).
None of the five defects in ALK1 were found in 150
normal chromosomes; therefore, they are unlikely to
represent silent polymorphisms. Each of the amino
acid alterations has been conserved through evolution
and across related type I receptors of the TGF-b su-
perfamily (Fig. 4).
Histologic assessment of the pulmonary vasculature
was available for four patients from Families 1 and 3.
Each had characteristic features of end-stage plexo-
genic pulmonary hypertension similar to those seen
in patients with primary pulmonary hypertension (Fig.
5).2 Immunohistochemical analysis demonstrated ex-
pression of activin-receptor–like kinase 1 to be pre-
dominantly in the vascular endothelium of normal and
diseased lungs (Fig. 5); activin-receptor–like kinase 1
colocalized with the CD31 endothelial-cell marker in
serial sections. Expression of activin-receptor–like ki-
nase 1 was also observed in the endothelium of occlu-
sive and plexiform lesions (Fig. 5).
In our study the clinical, hemodynamic, and histo-
logic features of pulmonary hypertension associated
with mutations in ALK1 were indistinguishable from
the features of pulmonary hypertension due to occlu-
sive vascular lesions associated with defects in BMPR2
(Fig. 5).10,11,20,21
DISCUSSION
The histologic and pathophysiological features of
hereditary hemorrhagic telangiectasia and primary pul-
monary hypertension might seem to be distinct. Pul-
Figure 3. Pedigrees of Families 2, 3, 4, 5, and 6 with Coexisting Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia.
Asterisks indicate family members whose DNA was analyzed, and arrows denote probands. The dotted lines in Family 5 indicate
adoption. The symbols in the pedigrees are the same as in Figure 2.
I
II
III
IV
Family 2 Family 3
1
1* 42*3*
1*
4*
8*
2
1 2* 3*5*
2*
6
2* 5* 6* 7*
21*
4*1* 3 1 2 3* 4 5
2*1
2* 3*
I
II
III
IV
V
Family 4
1
3 4
5*
2
21 1*
3
32
1* 2* 4*
1 2
Family 5
1 2
3 4
1*
1 3*2
1*
Family 6
1
2
2
1
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*Plus signs indicate the presence of a characteristic, and minus signs the absence of a characteristic. HHT denotes hereditary hemorrhagic
telangiectasia, NK not known, AVM arteriovenous malformation, PH pulmonary hypertension (defined as a mean pulmonary arterial pressure
greater than 25 mm Hg at rest), PAP pulmonary arterial pressure, CO cardiac output, CI cardiac index (defined as cardiac output divided
by body-surface area; normal range, 2.5 to 4.0 liters per minute per square meter), PAWP pulmonary-artery wedge pressure (normal range,
4 to 12 mm Hg), PVR pulmonary vascular resistance (mean pulmonary arterial pressure minus pulmonary-artery wedge pressure divided by
cardiac output; normal range, 1.0 to 2.5 resistance units), HLT heart–lung transplant, DLT double-lung transplant, and SLT single-lung
transplant.
†No family history was available for this patient, who was adopted.
‡The current ages of the surviving subjects, Subject V-1 from Family 4 and Subject V-1 from Family 6, are 28 and 20 years, respectively.
§A substitution of glutamic acid for arginine at position 67 in exon 3 of ALK1 was detected in Subject III-2 in Family 6 that was not
inherited by Subjects IV-3, V-1, and V-2.
¶L13fs(+1aa) indicates a premature truncation one amino acid after the mutation in the leucine residue at codon 13.
¿Del3' indicates a partial deletion of the 3' end of BMPR2, including exon 12, detected in DNA available from Subjects V-1 and IV-4 in
Family 6.
TABLE 1. CLINICAL FEATURES AND MUTATIONS IN SUBJECTS WITH PULMONARY HYPERTENSION AND A PERSONAL 
OR FAMILY HISTORY OF HEREDITARY HEMORRHAGIC TELANGIECTASIA.*
CHARACTERISTIC SUBJECT (FAMILY)
III-1
(1)
III-2
(1)
III-3
(1)
II-6
(2)
II-1
(3)
II-4
(3)
V-1
(4)
II-1†
(5)
V-1
(6)
V-2
(6)
Sex M M F M F F F F F M
Age at death (yr)‡ 7 2 9 46 50 34 39 10
Known features of HHT
Family history of HHT
Epistaxis
Telangiectasia
Pulmonary AVM
Hepatic AVM
Other AVM
Estrogen therapy
+
–
–
–
–
–
¡
+
¡
¡
¡
¡
¡
¡
+
+
+
¡
¡
¡
¡
+
+
+
¡
¡
¡
+
+
+
+
+
¡
¡
¡
+
¡
+
¡
¡
¡
+
+
¡
¡
¡
¡
¡
¡
NK
¡
¡
+
+
Uterine
¡
+
¡
¡
¡
¡
¡
¡
+
¡
¡
¡
¡
¡
¡
Known features of PH 
Age at onset (yr)
Family history of PH
6.0
+
1.5
+
1.5
+
29.0
¡
45.0
+
31.0
+
27.0
¡
33.0
NK
19.0
+
8.0
+
Symptoms at onset
Breathlessness
Fatigue
Syncope
Chest pain
¡
+
+
¡
+
¡
+
¡
+
+
¡
¡
+
¡
¡
¡
+
¡
¡
+
+
¡
¡
+
+
¡
¡
¡
+
¡
¡
¡
+
–
+
+
+
¡
+
+
Right-sided heart catheter-
ization
Mean PAP (mm Hg)
CO (liters/min)
CI (liters/min/m2)
PAWP (mm Hg)
PVR (resistance units)
Response to vasodilators
¡
¡
¡
¡
¡
NK
55
0.86
1.56
9
53.5
No
120
¡
¡
¡
¡
NK
74
4.82
2.50
7
13.9
No
45
4.81
¡
5
8.3
NK
55
6.90
4.40
7
7.0
NK
70
2.90
1.43
10
20.7
No
54
2.97
1.75
7
15.8
No
66
3.80
2.42
4
16.3
No
95
2.15
1.90
10
39.5
No
Treatment
Vasodilators
Transplantation
¡
¡
¡
¡
¡
HLT
¡
¡
¡
DLT
¡
SLT
+
¡
+
¡
+
¡
¡
¡
Histology of the lung
Explant
Autopsy
¡
+
¡
¡
+
¡
¡
¡
+
¡
+
¡
¡
¡
¡
¡
¡
¡
¡
¡
ALK1 mutation
Exon§
Amino acid position
Type of mutation
10
R484W
Missense
10
R484W
Missense
10
R484W
Missense
8
R411W
Missense
6
254delD
Deletion
6
254delD
Deletion
10
Q490X
Nonsense
2
L13fs(+1aa)¶
Frame shift
¡
¡
¡
¡
¡
¡
BMPR2 mutation¿ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ del3' del3'
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monary arteriovenous dilatation is the hallmark of lung
involvement in hereditary hemorrhagic telangiectasia,
leading to decreased pulmonary vascular resistance and
increased cardiac output, with normal to low pulmo-
nary arterial pressure.14,30 In contrast, primary pul-
monary hypertension is characterized by obliteration
of small pulmonary arteries, leading to increased pul-
monary vascular resistance, marked elevation of pul-
monary arterial pressure, and ultimately, a reduction
in cardiac output.1
We identified a total of 10 subjects with pulmonary
hypertension from 5 families with hereditary hemor-
rhagic telangiectasia and 1 subject with no available
family history. In each of these subjects, we excluded
left-ventricular high-output failure secondary to sys-
temic arteriovenous malformations and thromboem-
bolic disease after estrogen therapy for telangiecta-
ses12,13 as potential causes of elevated pulmonary
arterial pressure. Of the four subjects from whom lung
tissue was available (Table 1), pulmonary arterial le-
sions similar to those reported among subjects har-
boring mutations in BMPR2 were observed (Fig. 5).2
Since the clinical and histologic features of these sub-
jects resembled those of subjects with primary pul-
monary hypertension, we considered the possibility
that the association with hereditary hemorrhagic telan-
giectasia reflected basic defects underlying the inher-
ited predisposition to pulmonary hypertension.
Molecular analysis of these kindreds demonstrated
that mutations in ALK1 may lead to occlusion of the
pulmonary arteries together with vascular dilatation
manifested as telangiectasia and arteriovenous malfor-
mations. This apparent dichotomy may be explained
in part by current knowledge of the TGF-b signaling
pathway (Fig. 1). After ligand binding, a type II recep-
tor (for example, bone morphogenetic protein recep-
tor II) forms a heteromeric complex with a type I
receptor (for example, activin-receptor–like kinase 1)
and may associate with an accessory receptor such as
endoglin. This results in activation of the kinase do-
main of the type I receptor, initiating phosphorylation
of cytoplasmic proteins and subsequent gene tran-
scription.31
Immunohistochemical analysis demonstrated the
presence of activin-receptor–like kinase 1 in diseased
pulmonary vascular endothelium, suggesting that this
cell type is critical to the pathogenesis of both hered-
itary hemorrhagic telangiectasia and pulmonary hyper-
Figure 4. ALK1 and Identified Mutations.
ALK1 encodes a serine–threonine kinase; the hatched area denotes the sequence encoding the signal peptide, the black area the
sequence encoding the transmembrane region, and the gray area the sequence encoding the kinase domain. Previously reported
mutations in ALK1 are shown above the ALK1 complementary DNA (cDNA).17,26-28 The mutations in ALK1 detected in the families
in this study and their nucleotide positions are shown below the ALK1 cDNA. Circles denote missense mutations (amino acid sub-
stitutions), squares nonsense mutations (an amino acid replaced by a stop codon), triangles deletions of a nucleotide, crosses in-
sertions of a nucleotide, and the diamond both the insertion and the deletion of nucleotides. The gray circle denotes the missense
mutation in ALK1 detected in Family 6.26 Beneath these symbols, the homology results show the similarity of human activin-recep-
tor–like kinase 1 to mouse activin-receptor–like kinase 1 and other human type I receptors in the TGF-b family (i.e., activin-receptor–
like kinases 2, 3, 4, 5, and 6). Amino acid positions are shown in bold (254, 411, and 484), with the deletion of aspartic acid (D) and the
substitutions of arginine (R) for tryptophan (W).
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Figure 5. Photomicrographs of Paraffin-Embedded Lung Sections from a Control Subject (Panel A) and Subjects with Plexogenic
Pulmonary Hypertension and Mutations in ALK1 (Panels B, C, D, E, and F).
Histologic analysis of normal lung shows thin-walled peripheral pulmonary arteries (open arrow in Panel A) and normal alveolar
capillaries (solid arrows in Panel A). In contrast, regions of the alveolar capillary bed in subjects with pulmonary hypertension show
capillary dilatation (arrows in Panel B), the presence of plexiform lesions composed of thin-walled capillary channels (arrows in
Panel C), and thick-walled peripheral pulmonary arteries occluded by a cellular intimal proliferation (arrows in Panel D). Immuno-
histochemical analysis performed with a polyclonal antibody against activin-receptor–like kinase 1 demonstrated cellular localiza-
tion of activin-receptor–like kinase 1 to the pulmonary vascular endothelium in normal arteries and in arteries of patients with pul-
monary hypertension (arrows in Panel E), including the capillary channels containing occlusive and plexiform lesions (arrows in
Panel F). The sections in Panels A, B, C, and D were stained with hematoxylin and eosin. The sections in Panels E and F were coun-
terstained with hematoxylin. (Panels A, B, C, D, and F, approximately ¬200; Panel E, ¬800.)
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tension. TGF-b signaling affects both vascular differ-
entiation and proliferation, and overexpression of the
TGF-b1 ligand promotes intimal growth and apopto-
sis simultaneously in vascular endothelium.32 The plei-
otropic nature of TGF-b as a growth factor offers a
potential explanation for the variable complications of
hereditary hemorrhagic telangiectasia. The net effect
of dysfunction of activin-receptor–like kinase 1 may
depend on local vascular interactions and other envi-
ronmental or genetic factors.
The majority of defects in BMPR2 in patients with
primary pulmonary hypertension are predicted to gen-
erate either a substantially truncated protein or a re-
duction in the functional activity of the mature pro-
tein, a mechanism known as haploinsufficiency.21 The
deletion of the cytosine residue at position 37 in ALK1
is predicted to result in a markedly abbreviated tran-
script, suggesting that a similar mechanism perturbs
the function of activin-receptor–like kinase 1 in in-
herited pulmonary hypertension associated with he-
reditary hemorrhagic telangiectasia. No mutations in
ALK1 were identified in 35 subjects with isolated pri-
mary pulmonary hypertension.
The management of pulmonary hypertension in
patients with mutations in ALK1 should include a
careful assessment for recognized complications of he-
reditary hemorrhagic telangiectasia. Pulmonary arte-
riovenous malformations are considered to be more
common among patients with defects in endoglin,33
yet we identified such lesions in two subjects with
mutations in ALK1. The possibility of pulmonary as
well as systemic vascular malformations should be con-
sidered in all patients with hereditary hemorrhagic tel-
angiectasia, irrespective of genotype. Similarly, the
possibility of hereditary hemorrhagic telangiectasia
should be considered in any patient who presents with
unexplained pulmonary hypertension.
Our findings suggest that the TGF-b signaling path-
way is an important mechanism for the pathogenesis
of pulmonary hypertension. Defects in activin-recep-
tor–like kinase 1 may trigger divergent signaling path-
ways that remodel the pulmonary artery, resulting in
dilated and occlusive vascular phenotypes. Genes that
encode other components of the TGF-b pathway, or
those that are transcriptionally regulated by the path-
way, might also be associated with pulmonary hyper-
tension.
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